Advancing Neuromuscular Research and Care: Highlights from the 2025 NMD4C Annual Meeting
Last month, NMD4C hosted its 2025 Annual Meeting in Ottawa
It was a full day of collaborative sessions, strategic discussions and networking that brought together clinicians, researchers, trainees, and partners from across Canada to advance neuromuscular research and care.
Meeting highlights included:
- A recognition ceremony celebrating Early Career awardees and NM fellowship funding recipients
- Flash talk presentations showcasing the work of early-career researchers
- Networking breaks to foster collaboration and community building
- Parallel group discussions to address key priorities in neuromuscular research and care:
-
- Clinical Sessions explored:
- Implementation strategies and awareness-building for new SBMA guidelines
- Health administrative data linkage for SBMA, OPMD, SMA, and DMD with the CNDR
- Barriers to implementing MRI and ultrasound into clinical practice
- Planning for gene therapy in Canada
- Development of combination treatment guidelines for SMA
- Establishing and integrating DM1 outcome measures with CNDR datasets
- Cross-disciplinary and Basic Science Sessions focused on:
- Collaborative grant design and funding pathway exploration
- Academic retention and postdoc-to-PI transition support
- Enhancing access to shared resources and fostering preclinical-clinical collaborations
- Synthesizing insights to prioritize next steps for cross-disciplinary initiatives
- Clinical Sessions explored:
We extend our sincere thanks to our funders — Muscular Dystrophy Canada (MDC) and the Canadian Institutes of Health Research (CIHR) — and to all members, discussion leads, and partners who contributed to the success of this event.
Together, we are strengthening Canada’s neuromuscular research and care community.
We look forward to hosting our 2026 Annual Meeting just ahead of the WCNMC 2026 in Calgary on September 25, 2026!
See snapshots of the annual meeting in Our Gallery
Read next...
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.
New Best Practice Recommendations for SBMA Care in Canada
Congratulations to Dr. Kerri Schellenberg, the team of Canadian experts, NMD4C Steering Committee members and Investigators, on publishing the first Canadian SBMA care guidelines!
NMD4C Hosts Inaugural Clinical Summer School to Empower Canada’s Future Neuromuscular Leaders
On September 10–11, NMD4C hosted its inaugural Clinical Summer School in Ottawa, bringing together 19 neuromuscular clinical fellows from across Canada for two days of hands-on training, mentorship, and networking. Led by national experts and co-chaired by Drs. Gordon Jewitt and Marianne Nury, the program complemented NMD4C’s accredited lecture series and fostered peer connection through dedicated community-building sessions.
2026 Neuromuscular Postdoctoral Research Fellowships Funding Competition is Now Open!
Apply Or Share this opportunity with the trainees in your network — Deadline: October 14, 2025. Hosted by Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC)
Announcing the 2026 Neuromuscular Clinical Fellowship Award Recipients
We are excited to share that the 2026 Neuromuscular Clinical Fellowship Awards have been awarded! These fellowships strengthen clinical training in neuromuscular medicine and help prepare the next generation of specialists who will advance neuromuscular care across Canada.
NMD4C Launches Clinical Summer School
We are excited to announce our inaugural Clinical Summer School, happening in Ottawa, Ontario on September 10–11, 2025. The event will feature hands-on workshops designed to complement the NMD4C Royal College–accredited National Neuromuscular Lecture Series and foster engagement among fellows.